$1.00
+0.00 (+0.00%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AURX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 1 tracked-famous manager (Ancora Advisors LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Effectiveness of Aurix Therapy in Venous Leg UlcersNCT02352454Time to HealRandomized · Open-label · Treatment | Not applicable | Unknown status | Device: Aurix | Venous Leg Ulcers | 640 | Jul 2018 | 2018-01-25 |
| Effectiveness of Aurix Therapy in Pressure UlcersNCT02352467Time to HealRandomized · Open-label · Treatment | Not applicable | Unknown status | Device: Aurix | Pressure Ulcer | 800 | Jul 2018 | 2018-01-25 |
| Effectiveness of Aurix Therapy in Diabetic Foot UlcersNCT02352480Time to healRandomized · Open-label · Treatment | Not applicable | Unknown status | Device: Aurix | Diabetic Foot Ulcers | 760 | Jul 2018 | 2018-01-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19